No Data
No Data
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst
Ionis Pharmaceuticals Inc (NASDAQ:IONS) released results Monday from the completed multiple ascending dose (MAD) portion of the Phase 1/2 open-label study of ION582 in people with Angelman syndrome (
Alnylam Pharmaceuticals Is Maintained at Neutral by Cantor Fitzgerald
Alnylam Pharmaceuticals Is Maintained at Neutral by Cantor
Alnylam Pharmaceuticals Price Target Raised to $220.00/Share From $150.00 by Cantor Fitzgerald
Alnylam Pharmaceuticals Price Target Raised to $220.00/Share From $150.00 by Cantor
Express News | Cantor Fitzgerald Maintains Neutral on Alnylam Pharmaceuticals, Raises Price Target to $220
Market Sentiment Around Loss-Making Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
$100 Invested In This Stock 20 Years Ago Would Be Worth $4,100 Today
Alnylam Pharmaceuticals (NASDAQ:ALNY) has outperformed the market over the past 20 years by 12.59% on an annualized basis producing an average annual return of 21.02%. Currently, Alnylam
151652693 : There are many theories that do not touch the QE factor that caused the rise and harvest of global finance
151336027 :
151830249 :
151078437 :
151817588 :
View more comments...